Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263050 · ClinicalTrials.gov registry record · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
A Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 1
- Study location
NCT05263050: Recruiting Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma, sponsored by Fox Chase Cancer Center.
NCT05263050 is a Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 111 participants, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05263050, a Phase 2 study of Neuroendocrine Tumors and Metastatic Renal Cell Carcinoma, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
Primary Outcome
To show that alternative cabozantinib dosing can improve average daily dose compared to historical controls
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Cabozantinib
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What NCT05263050 shows while recruiting
NCT05263050 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 178-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (38% lower).
The record links to 4 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT05263050 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05263050 about?
NCT05263050 is a clinical study titled "Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors". This is a multi-site, three-cohort phase II trial of cabozantinib for IMDC all-risk frontline metastatic renal cell carcinoma (mRCC) patients OR any line mRCC patients who have not previously been treated with cabozantinib, and patients with pancreatic or extra-pancreatic neuroendocrine tumors.
What is the current status of trial NCT05263050?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2022-01-21. Estimated completion is 2027-02.
What conditions does trial NCT05263050 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Metastatic Renal Cell Carcinoma, Carcinoid Tumor, Clear-cell Metastatic Renal Cell Carcinoma.
What interventions are being tested in trial NCT05263050?
The interventions under investigation include: Nivolumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05263050?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263050 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05263050's enrollment target sits among peer trials
111 21st of 52 higher than 32 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
- NCT05640102 · 111 participants
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI